FYERS
Home
/
Stocks
/
Results
/
Aarti Pharmalabs Results

Aarti Pharmalabs Results

Financial overview

CAGR%
Sales
Profits
Returns
ROE
10Y5Y3YTTM
---2%-14%
---3%-36%
--31%-1%
11%14%12%9%

Peer Comparison

Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
ZYDUSLIFE
CIPLA
LAURUSLABS
LUPIN
MANKIND
DRREDDY
AUROPHARMA
AARTIPHARM
PriceM.Cap (₹)PE RatioEPS (₹)EV/EBITDAAnnual PAT
1,901.6₹456833 Cr37.7712.0762.82₹11479 Cr
9,180.5₹245426 Cr83.9134.04128.41₹2568 Cr
4,861.5₹187320 Cr85.8916.7297.06₹2163 Cr
1,131.1₹113217 Cr25.099.4262.53₹5040 Cr
1,380.1₹112212 Cr33.299.7757.87₹3879 Cr
1,852.6₹101155 Cr92.526.829.25₹889 Cr
2,123₹97626 Cr17.6630.95154.36₹5333 Cr
2,335.2₹96859 Cr47.4213.7571.08₹1913 Cr
1,162₹96406 Cr29.925.3263.99₹4196 Cr
1,656.5₹93614 Cr25.2217.9596.84₹3505 Cr
858.65₹7852 Cr36.848.435.81₹175 Cr

Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
₹536 Cr₹583 Cr₹432 Cr₹418 Cr₹386 Cr₹564 Cr₹538 Cr₹458 Cr₹555 Cr₹506 Cr₹449 Cr₹440 Cr₹458 Cr₹485 Cr₹472 Cr₹531 Cr₹457 Cr₹460 Cr
₹45 L₹8 Cr-₹37 L₹5 L₹77 L₹86 L₹5 Cr₹4 Cr₹2 Cr₹2 Cr₹1 Cr₹99 L₹48 L₹74 L₹29 L₹1 Cr₹2 L₹3 Cr
₹536 Cr₹591 Cr₹432 Cr₹418 Cr₹387 Cr₹565 Cr₹543 Cr₹463 Cr₹558 Cr₹508 Cr₹450 Cr₹441 Cr₹459 Cr₹486 Cr₹472 Cr₹532 Cr₹457 Cr₹463 Cr
₹430 Cr₹498 Cr₹359 Cr₹368 Cr₹318 Cr₹443 Cr₹432 Cr₹385 Cr₹479 Cr₹407 Cr₹372 Cr₹370 Cr₹391 Cr₹421 Cr₹402 Cr₹458 Cr₹385 Cr₹399 Cr
₹137 Cr₹121 Cr₹102 Cr₹75 Cr₹92 Cr₹144 Cr₹134 Cr₹98 Cr₹99 Cr₹120 Cr₹97 Cr₹89 Cr₹85 Cr₹81 Cr₹87 Cr₹91 Cr₹86 Cr₹78 Cr
₹13 Cr₹17 Cr₹13 Cr₹11 Cr₹7 Cr₹7 Cr₹10 Cr₹6 Cr₹5 Cr₹5 Cr₹4 Cr₹4 Cr₹4 Cr₹6 Cr₹5 Cr₹6 Cr₹4 Cr₹5 Cr
₹94 Cr₹76 Cr₹58 Cr₹39 Cr₹63 Cr₹115 Cr₹101 Cr₹72 Cr₹74 Cr₹96 Cr₹74 Cr₹67 Cr₹64 Cr₹59 Cr₹65 Cr₹69 Cr₹68 Cr₹59 Cr
₹69 Cr₹56 Cr₹43 Cr₹29 Cr₹48 Cr₹88 Cr₹74 Cr₹55 Cr₹55 Cr₹65 Cr₹53 Cr₹52 Cr₹47 Cr₹43 Cr₹48 Cr₹51 Cr₹52 Cr₹49 Cr

Balance Sheet

Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Secured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
——————
₹45 Cr₹45 Cr₹45 Cr₹45 Cr₹25 L₹25 L
₹3 Cr₹2 Cr₹23 L₹0₹45 Cr₹0
₹2076 Cr₹1943 Cr₹1712 Cr₹1513 Cr₹1341 Cr-₹2 L
₹2076 Cr₹1943 Cr₹1712 Cr₹1513 Cr₹1341 Cr-₹2 L
₹2125 Cr₹1990 Cr₹1757 Cr₹1558 Cr₹1386 Cr₹23 L
₹186 Cr₹104 Cr₹4 L₹18 L₹55 L₹0
₹134 Cr₹128 Cr₹108 Cr₹79 Cr₹71 Cr₹0
₹92 Cr₹19 Cr₹17 Cr₹53 L₹2 Cr₹0
₹8 Cr₹8 Cr₹6 Cr₹5 Cr₹0₹0
₹420 Cr₹259 Cr₹131 Cr₹85 Cr₹73 Cr₹0
——————
₹335 Cr₹278 Cr₹378 Cr₹340 Cr₹215 Cr₹26,000
₹135 Cr₹70 Cr₹46 Cr₹38 Cr₹12 Cr₹20,000
₹457 Cr₹293 Cr₹264 Cr₹214 Cr₹338 Cr₹2 L
₹11 Cr₹13 Cr₹6 Cr₹9 Cr₹16 Cr₹0
₹938 Cr₹653 Cr₹694 Cr₹601 Cr₹581 Cr₹2 L
₹3482 Cr₹2902 Cr₹2582 Cr₹2244 Cr₹2040 Cr₹25 L
₹8 Cr₹14 Cr₹7 Cr₹7 Cr₹0₹0
₹686 Cr₹396 Cr₹264 Cr₹214 Cr₹339 Cr₹2 L
——————
₹2135 Cr₹1796 Cr₹1609 Cr₹1431 Cr₹1225 Cr₹0
₹697 Cr₹659 Cr₹576 Cr₹505 Cr₹443 Cr₹0
₹1437 Cr₹1137 Cr₹1033 Cr₹926 Cr₹782 Cr₹0
₹305 Cr₹307 Cr₹78 Cr₹62 Cr₹165 Cr₹0
₹194 Cr₹29 Cr₹37 Cr₹36 Cr₹32 Cr₹0
₹194 Cr₹29 Cr₹37 Cr₹36 Cr₹32 Cr₹0
₹60 Cr₹44 Cr₹29 Cr₹18 Cr₹10 Cr₹0
₹2084 Cr₹1584 Cr₹1236 Cr₹1081 Cr₹1012 Cr₹0
——————
₹0₹48 Cr₹70 Cr₹51 Cr₹0₹0
₹640 Cr₹588 Cr₹643 Cr₹602 Cr₹475 Cr₹0
₹583 Cr₹575 Cr₹519 Cr₹450 Cr₹377 Cr₹0
₹10 Cr₹9 Cr₹24 Cr₹12 Cr₹83 Cr₹25 L
₹12 Cr₹12 Cr₹17 Cr₹8 Cr₹11 Cr₹0
₹152 Cr₹87 Cr₹72 Cr₹40 Cr₹82 Cr₹0
₹1397 Cr₹1318 Cr₹1346 Cr₹1163 Cr₹1028 Cr₹25 L
₹460 Cr₹665 Cr₹651 Cr₹562 Cr₹447 Cr₹23 L
₹3482 Cr₹2902 Cr₹2582 Cr₹2244 Cr₹2040 Cr₹25 L
₹234₹219₹194₹172₹53,647₹9
₹234₹219₹194₹172₹53,647₹9

Cash Flow

Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Closing Cash & Cash Equivalent
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
₹228 Cr₹361 Cr₹300 Cr₹261 Cr₹155 Cr-₹46,000
₹188 Cr₹120 Cr₹95 Cr₹83 Cr₹52 Cr₹0
-₹107 Cr-₹86 Cr-₹122 Cr-₹32 Cr-₹230 Cr₹46,000
₹309 Cr₹395 Cr₹273 Cr₹312 Cr-₹23 Cr₹0
₹262 Cr₹330 Cr₹216 Cr₹250 Cr-₹44 Cr₹0
-₹431 Cr-₹412 Cr-₹215 Cr-₹158 Cr-₹139 Cr₹0
₹171 Cr₹65 Cr₹10 Cr-₹163 Cr₹260 Cr₹0
₹2 Cr-₹17 Cr₹12 Cr-₹71 Cr₹78 Cr₹0
₹7 Cr₹24 Cr₹12 Cr₹83 Cr₹5 Cr₹25 L
₹9 Cr₹7 Cr₹24 Cr₹12 Cr₹83 Cr₹25 L

Fundamental Ratios

Consolidated
Standalone
Empty box

No results found

Share Price Live Stats

Open (₹)872.00
Volume (₹)2.90 L
High (₹)879.75
Upper Circuit1,041.70
Low (₹)854.10
Lower Circuit694.50
Prev Close868.10
52W High (₹)946.10
Price858.65
52W Low (₹)585.00

Share Market Cap & Key Ratios Overview

M.Cap (₹)7852.42 Cr
Div. Yield (%)0.40
PE Ratio36.84
Debt to Equity0.32
Price to Book2.52
Book Value234.02
EPS (TTM)23.51
Face Value5.00
ROE (%)8.50

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
LUPINNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
AARTIPHARMNSE
LTP
1W Low
1W High
Market cap (₹)
1901.6-18.4 (-0.96%)
1900.10
1984.80
4,56,833Cr
9180.5-58.5 (-0.63%)
9087
9467
2,45,426Cr
4861.5-188.5 (-3.73%)
4857
5066
1,87,320Cr
1131.4-59.6 (-5.00%)
1125.10
1187
1,13,217Cr
1380.7-42.8 (-3.01%)
1376.70
1426.10
1,12,212Cr
1852.9-85.6 (-4.42%)
1811.70
1949
1,01,155Cr
2123-48.5 (-2.23%)
2118.10
2192
97,626Cr
2335.2-47.7 (-2.00%)
2335
2419.20
96,859Cr
1161.6-16.4 (-1.39%)
1154.40
1179.90
96,406Cr
1656.5+11.2 (0.68%)
1622.60
1717
93,614Cr
858.65+17.95 (2.14%)
829
886.95
7,852Cr

Aarti Pharmalabs Ltd Annual Results Key Takeaways

Operating profit (before other income, interest and exceptional items) was ₹136.56Cr; with other income of ₹45.3Lakh, profit before interest and tax came to ₹106.53Cr. Interest expense was ₹12.88Cr; PBT before exceptional items stood at ₹93.66Cr. Cost mix (full year): raw materials ₹886.01Cr; employee cost ₹163.02Cr; depreciation ₹30.03Cr; other expenses ₹399.69Cr. Basis: consolidated annual results.

Aarti Pharmalabs Ltd Quaterly Results Key Takeaways

Aarti Pharmalabs Ltd reported ₹535.8Cr total income from operations in Jun 2026, softer than ₹582.64Cr in Mar 2026 but higher than ₹386.19Cr in Jun 2025. Operating profit (before other income, interest and exceptional items) was ₹136.56Cr; with other income of ₹45.3Lakh, profit before interest and tax came to ₹106.53Cr. Interest expense was ₹12.88Cr, taking profit before tax to ₹93.66Cr. After tax of ₹24.92Cr, profit after tax stood at ₹68.74Cr (vs ₹55.61Cr in Mar 2026 and ₹47.83Cr in Jun 2025).